The verdict
Our read at a glance.
Whether thymosin beta-10/TMSB10 evidence supports any human therapeutic, biomarker, product-identity, or safety claim beyond endogenous biology and disease-association signals.
- The signal
- The strongest signal is a large academic footprint in cancer biomarker and prognosis studies, developmental-expression papers, actin-monomer sequestration work, and tumor-biology mechanisms. These sources can support a cautious biology and association memo. They do not establish thymosin beta-10 as a treatment, clinical decision tool, safe product, or validated intervention.
- The unknown
- Whether any TMSB10 signal has durable clinical utility once separated from retrospective biomarker associations, cell and animal mechanisms, broad beta-thymosin family evidence, and product identities that have not been tested as thymosin beta-10 interventions.
- Our read
- Real biology, weak translation. TMSB10 has a deep biomarker and disease-biology literature, much of it in oncology. That work describes what the protein does in disease; it is not a basis for clinical-use, immune, regenerative, cancer-treatment, or product-safety claims.
The mechanism
How it works.
Thymosin beta-10 is a small protein made naturally inside cells, part of the beta-thymosin family. Its established job is to grab loose actin monomers and hold them in reserve, which controls how fast cells build and dismantle their internal scaffolding and therefore how they change shape, move, and divide. Because that scaffolding turnover ramps up in growing and migrating cells, the protein shows up at high levels in many tumors, so most of the human data treats it as a measured marker of cancer biology rather than as anything given as a treatment.
Safety & regulatory boundary
The consequential part.
Public checks did not identify a U.S. FDA-approved thymosin beta-10 drug, DailyMed SPL label, exact RxNorm drug concept, or direct ClinicalTrials.gov intervention record as of 2026-05-16. The single exact ClinicalTrials.gov marker-context hit is not thymosin beta-10 therapy or product development. TMSB10 should not be treated as interchangeable with thymosin beta-4/TB-500, thymosin alpha-1/thymalfasin/Zadaxin, Thymalin, thymulin/nonathymulin, thymus extracts, broad thymosin-family claims, compounded products, research-use products, or internet-market products.
What's next
What we're watching.
Watch for direct human intervention trials, product-specific regulatory records, validated clinical-utility studies, dedicated safety data for a defined thymosin beta-10 product, and higher-quality reviews that separate endogenous TMSB10 biology from therapeutic or internet-market claims.
Context
Why this is discussed.
Thymosin beta-10 is often discussed near other thymic peptides, but the credible literature is mostly about endogenous TMSB10 expression, actin/cytoskeleton biology, tumor markers, prognosis, developmental expression, and cell-state mapping.
The evidence base
66 cited references.
Regulatory & labels1
Food and Drug Administration · Checked 2026-05-16
Registered trials1
ClinicalTrials.gov / Meyer Children's Hospital IRCCS · First posted 2024-03-22; checked 2026-05-16
Indexed literature (PubMed)61
McCreary V et al. · 1988
Wang GX et al. · 2026
Xia H et al. · 2025
Zahran FM et al. · 2024
Yang J et al. · 2024
Li Z et al. · 2023
Xiong Y et al. · 2022
Wang C et al. · 2022
Yan Z et al. · 2021
Li J et al. · 2021
Zeng J et al. · 2020
Pan Q et al. · 2020
Wang B et al. · 2019
Song C et al. · 2019
Zhang X et al. · 2017
Bosello S et al. · 2016
Bouchal P et al. · 2015
Wang H et al. · 2014
Zhang XJ et al. · 2014
Theunissen W et al. · 2014
Sribenja S et al. · 2013
Feher LZ et al. · 2012
Lee SM et al. · 2011
Hardesty WM et al. · 2011
Huang L et al. · 2011
Li M et al. · 2009
Inzitari R et al. · 2009
Chiappetta G et al. · 2004
Takano T et al. · 2002
Otto AM et al. · 2002
Vasile E et al. · 2001
Lee SH et al. · 2001
Santelli G et al. · 1999
Califano D et al. · 1998
Verghese-Nikolakaki S et al. · 1996
Hall AK · 1994
Weterman MA et al. · 1993
Tantawy M et al. · 2023
Yu FX et al. · 1993
Erickson-Viitanen S et al. · 1983
Sun HQ and Yin HL · 2007
Nachmias VT · 1993
Volk DE et al. · 2012
Sribenja S et al. · 2013
Sribenja S et al. · 2009
Chen C et al. · 2005
Faa G et al. · 2024
Faa G et al. · 2012
Fanni D et al. · 2011
Gerosa C et al. · 2010
Hall AK et al. · 1990
Lin SC and Morrison-Bogorad M · 1990
Border BG et al. · 1993
Maelan AE et al. · 2007
Rho SB et al. · 2004
Lee SH et al. · 2005
Gutierrez-Pabello JA et al. · 2002
Kim YC et al. · 2012
Sponsor & other sources3
NCBI Gene · Updated 2026-04-08; checked 2026-05-16
HGNC · Modified 2023-01-20; checked 2026-05-16
UniProt Consortium · Reviewed entry checked 2026-05-16
Keep reading